150 related articles for article (PubMed ID: 38783246)
21. Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials.
Nguyen PL; Huang HR; Spratt DE; Davicioni E; Sandler HM; Shipley WU; Efstathiou JA; Simko JP; Pollack A; Dicker AP; Roach M; Rosenthal SA; Zeitzer KL; Mendez LC; Hartford AC; Hall WA; Desai AB; Rabinovitch RA; Peters CA; Rodgers JP; Tran P; Feng FY
Int J Radiat Oncol Biol Phys; 2023 Jul; 116(3):521-529. PubMed ID: 36596347
[TBL] [Abstract][Full Text] [Related]
22. Impact of family history on oncological outcomes in primary therapy for localized prostate cancer patients: a systematic review and meta-analysis.
Urabe F; Kimura S; Yamamoto S; Tashiro K; Kimura T; Egawa S
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):638-646. PubMed ID: 33589769
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of miR-21 for prostate cancer: a systematic review and meta-analysis.
Stafford MYC; Willoughby CE; Walsh CP; McKenna DJ
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34931228
[TBL] [Abstract][Full Text] [Related]
24. Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial.
Feng FY; Huang HC; Spratt DE; Zhao SG; Sandler HM; Simko JP; Davicioni E; Nguyen PL; Pollack A; Efstathiou JA; Dicker AP; Todorovic T; Margrave J; Liu YS; Dabbas B; Thompson DJS; Das R; Dignam JJ; Sweeney C; Attard G; Bahary JP; Lukka HR; Hall WA; Pisansky TM; Shah AB; Pugh SL; Shipley WU; Tran PT
JAMA Oncol; 2021 Apr; 7(4):544-552. PubMed ID: 33570548
[TBL] [Abstract][Full Text] [Related]
25. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
Gnanapragasam VJ; Lophatananon A; Wright KA; Muir KR; Gavin A; Greenberg DC
PLoS Med; 2016 Aug; 13(8):e1002063. PubMed ID: 27483464
[TBL] [Abstract][Full Text] [Related]
26. Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
Mehra R; Salami SS; Lonigro R; Bhalla R; Siddiqui J; Cao X; Spratt DE; Palapattu GS; Palanisamy N; Wei JT; Chinnaiyan AM; Tomlins SA
Med Oncol; 2018 Oct; 35(12):152. PubMed ID: 30291535
[TBL] [Abstract][Full Text] [Related]
27. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence.
Lee BH; Kibel AS; Ciezki JP; Klein EA; Reddy CA; Yu C; Kattan MW; Stephenson AJ
Eur Urol; 2015 Feb; 67(2):204-9. PubMed ID: 25294696
[TBL] [Abstract][Full Text] [Related]
28. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.
Pettersson A; Graff RE; Bauer SR; Pitt MJ; Lis RT; Stack EC; Martin NE; Kunz L; Penney KL; Ligon AH; Suppan C; Flavin R; Sesso HD; Rider JR; Sweeney C; Stampfer MJ; Fiorentino M; Kantoff PW; Sanda MG; Giovannucci EL; Ding EL; Loda M; Mucci LA
Cancer Epidemiol Biomarkers Prev; 2012 Sep; 21(9):1497-509. PubMed ID: 22736790
[TBL] [Abstract][Full Text] [Related]
29. Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure.
Jackson WC; Suresh K; Tumati V; Dess RT; Soni PD; Zhao SG; Zumsteg ZS; Hannan R; Hollenbeck BK; George A; Kaffenberger SD; Salami SS; Hearn JWD; Morgan TM; Mehra R; Schipper M; Feng FY; Desai NB; Spratt DE
Eur Urol Oncol; 2018 Sep; 1(4):276-282. PubMed ID: 31100248
[TBL] [Abstract][Full Text] [Related]
30. The Prognostic Impact of Intraductal Carcinoma of the Prostate: A Systematic Review and Meta-Analysis.
Miura N; Mori K; Mostafaei H; Quhal F; Motlagh RS; Pradere B; Laukhtina E; D'Andrea D; Saika T; Shariat SF
J Urol; 2020 Nov; 204(5):909-917. PubMed ID: 32698712
[TBL] [Abstract][Full Text] [Related]
31. Positive surgical margin is associated with biochemical recurrence risk following radical prostatectomy: a meta-analysis from high-quality retrospective cohort studies.
Zhang L; Wu B; Zha Z; Zhao H; Jiang Y; Yuan J
World J Surg Oncol; 2018 Jul; 16(1):124. PubMed ID: 29970100
[TBL] [Abstract][Full Text] [Related]
32. Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy.
Jackson W; Hamstra DA; Johnson S; Zhou J; Foster B; Foster C; Li D; Song Y; Palapattu GS; Kunju LP; Mehra R; Feng FY
Cancer; 2013 Sep; 119(18):3287-94. PubMed ID: 23821578
[TBL] [Abstract][Full Text] [Related]
33. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
[TBL] [Abstract][Full Text] [Related]
34. The impact of PTEN deletion and ERG rearrangement on recurrence after treatment for prostate cancer: a systematic review and meta-analysis.
Liu R; Zhou J; Xia S; Li T
Clin Transl Oncol; 2020 May; 22(5):694-702. PubMed ID: 31359337
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Value of Hemoglobin in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
Mori K; Janisch F; Mostafaei H; Lysenko I; Karakiewicz PI; Enikeev DV; Briganti A; Kimura S; Egawa S; Shariat SF
Clin Genitourin Cancer; 2020 Aug; 18(4):e402-e409. PubMed ID: 32007439
[TBL] [Abstract][Full Text] [Related]
36. A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy.
Jackson WC; Johnson SB; Li D; Foster C; Foster B; Song Y; Schipper M; Shilkrut M; Sandler HM; Morgan TM; Palapattu GS; Hamstra DA; Feng FY
Radiat Oncol; 2013 Jul; 8():170. PubMed ID: 23835115
[TBL] [Abstract][Full Text] [Related]
37. PITX2 methylation: a novel and effective biomarker for monitoring biochemical recurrence risk of prostate cancer.
Jiang Q; Xie M; He M; Yan F; Chen M; Xu S; Zhang X; Shen P
Medicine (Baltimore); 2019 Jan; 98(1):e13820. PubMed ID: 30608394
[TBL] [Abstract][Full Text] [Related]
38. Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases.
FitzGerald LM; Zhao S; Leonardson A; Geybels MS; Kolb S; Lin DW; Wright JL; Eeles R; Kote-Jarai Z; Govindasami K; Giles GG; Southey MC; Schleutker J; Tammela TL; Sipeky C; Penney KL; Stampfer MJ; Gronberg H; Wiklund F; Stattin P; Hugosson J; Karyadi DM; Ostrander EA; Feng Z; Stanford JL
Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):228-237. PubMed ID: 29298992
[TBL] [Abstract][Full Text] [Related]
39. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
[TBL] [Abstract][Full Text] [Related]
40. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.
Howard LE; Moreira DM; De Hoedt A; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ
BJU Int; 2017 Nov; 120(5B):E80-E86. PubMed ID: 28371163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
